Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 13, 2014, Pages 1797-1810

  Broadstock, Martin ^a   Ballard, Clive ^a   Corbett, Anne ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Clinical trials; Dementia; Dementia with Lewy bodies; Parkinson's disease dementia; Treatment

Indexed keywords

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG REPOSITIONING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LEWY BODY DISEASE; PARKINSON DISEASE;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG REPOSITIONING; HUMANS; IMMUNOTHERAPY; LEWY BODY DISEASE; PARKINSON DISEASE;

EID: 84905823855     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.936848     Document Type: Review

References (100)

1. Wimo A, Jonsson L, Bond J, et al. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013;9(1):1-11.e3
2. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10(9):698-712
3. Jones EL, Hanney M, Francis PT, et al. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci Lett 2009;451(2):162-4
4. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488(7409):96-9
5. Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet 2011;377(9770):1019-31
6. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863-72
7. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197-211
8. Lippa CF. Synaptophysin immunoreactivity in Pick's disease: comparison with Alzheimer's disease and dementia with Lewy bodies. Am J Alzheimers Dis Other Demen 2004;19(6):341-4
9. Wakabayashi K, Tanji K, Odagiri S, et al. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol 2013;47(2):495-508
10. Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4(6):428-30
11. Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. Curr Neurol Neurosci Rep 2012;12(5):492-501
12. Ballard C, Corbett A, Sharp S. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. Expert Rev Neurother 2011;11(3):327-9
13. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012;3:CD006504
14. Goldman JG, Goetz CG, Brandabur M, et al. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008;23(15):2248-50
15. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):311-21
16. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):322-33
17. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61(1):46-54
18. Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6(2):144-51
19. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372(9634):216-23
20. Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011;31(25):9323-31
21. Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, doubleblind, placebo-controlled, first-in-human study. Lancet Neurol 2012;11(7):597-604
22. Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis 2009;17(2):243
23. Bard F, Fox M, Friedrich S, et al. Sustained levels of antibodies against Abeta in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp Neurol 2012;238(1):38-43
24. Chiang K, Koo EH. Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol 2014;54:381-405
25. Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012;69(11):1430-40
26. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65(8):1031-8
27. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013;369(4):341-50
28. Gupta VB, Gupta VK, Martins R. Semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013;369(17):1660-1
29. Forman M, Palcza J, Tseng J, et al. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Ab peptides in healthy subjects following single-and multiple-dose administration. Alzheimers Dementia 2012;8(4 Suppl):P704
30. Cai J, Qi X, Kociok N, et al. Beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 2012;4(9):980-91
31. Kim DY, Gersbacher MT, Inquimbert P, et al. Reduced sodium channel Na(v) 1.1 levels in BACE1-null mice. J Biol Chem 2011;286(10):8106-16
32. Kobayashi D, Zeller M, Cole T, et al. BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. Neurobiol Aging 2008;29(6):861-73
33. Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 2014;88(4):529-39
34. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 2012;96(1):32-45
35. Stack C, Jainuddin S, Elipenahli C, et al. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet 2014; Epub ahead of print
36. Wischik CM, Bentham P, Wischik DJ, et al. Tau aggregation inhibitor (TAI) therapy with rember arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement 2008;4(4):T167
37. Spires-Jones TL, Friedman T, Pitstick R, et al. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci Lett 2014;562(0):63-8
38. Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68(8):853-61
39. Zhang X, Heng X, Li T, et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 2011;24(4):739-49
40. Straten G, Saur R, Laske C, et al. Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease. Curr Alzheimer Res 2011;8(8):853-9
41. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 2013;10(1):104-7
42. Marcade M, Bourdin J, Loiseau N, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 2008;106(1):392-404
43. Vellas B, Sol O, Snyder PJ, et al. EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 2011;8(2):203-12
44. Squitti R, Simonelli I, Ventriglia M, et al. Meta-analysis of serum nonceruloplasmin copper in Alzheimer's disease. J Alzheimers Dis 2014;38(4):809-22
45. Jenagaratnam L, McShane R. Clioquinol for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2006(1):CD005380
46. Ma T, Trinh MA, Wexler AJ, et al. Suppression of eIF2alpha kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat Neurosci 2013;16(9):1299-305
47. Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 2012;11(11):833-46
48. Bassil F, Fernagut PO, Bezard E, et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modificatioñ Prog Neurobiol 2014;118C:1-18
49. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70(6):440-8
50. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38
51. McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010;630(1-3):158-62
52. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012;122(4):1339-53
53. Corbett A, Ballard C. Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms? Expert Opin Investig Drugs 2013;22(8):941-3
54. Iwasaki K, Egashira N, Takagaki Y, et al. Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats. Biol Pharm Bull 2007;30(4):698-701
55. Kennelly SP, Abdullah L, Paris D, et al. Demonstration of safety in Alzheimer's patients for intervention with an antihypertensive drug Nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry 2011;26(10):1038-45
56. Kennelly S, Abdullah L, Kenny RA, et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients-an open-label trial. Int J Geriatr Psychiatry 2012;27(4):415-22
57. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162(18):2046-52
58. Forloni G, Colombo L, Girola L, et al. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001;487(3):404-7
59. Parachikova A, Vasilevko V, Cribbs DH, et al. Reductions in Amyloid-beta-Derived Neuroinflammation, with Minocycline, Restore Cognition but do not Significantly Affect Tau Hyperphosphorylation. J Alzheimers Dis 2010;21(2):527-42
60. Cuello AC, Ferretti MT, Leon WC, et al. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis 2010;7(1-3):96-8
61. Ding Y, Qiao AM, Wang ZQ, et al. Retinoic Acid Attenuates beta-Amyloid Deposition and Rescues Memory Deficits in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 2008;28(45):11622-34
62. Jarvis CI, Goncalves MB, Clarke E, et al. Retinoic acid receptor-alpha signalling antagonizes both intracellular and extracellular amyloid-beta production and prevents neuronal cell death caused by amyloid-beta. Eur J Neurosci 2010;32(8):1246-55
63. Wright JW, Harding JW. Brain renin-angiotensin-A new look at an old system. Prog Neurobiol 2011;95(1):49-67
64. Li N-C, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. Br Med J 2010;340:b5465
65. Davies N, Kehoe P, Ben-Shlomo Y, et al. Associations of angiotensin-II receptor blockers and ace inhibitors with Alzheimer's disease: a nested case-control study within the UK General Practice Research Database. J Epidemiol Commun Health 2011;65:A45-A
66. Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011;10(1):43-53
67. Lithell H, Hansson L, Skoog I, et al. The Study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21(5):875-86
68. Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function and anti hypertensive treatment on cognitive and cardiovascular outcomes: study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005;18(8):1052-9
69. O'Caoimh R, Healy L, Gao Y, et al. Effects of Centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. J Alzheimers Dis 2014;40(3):595-603
70. Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011;3(2):16
71. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289(21):2819-26
72. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302(23):2557-64
73. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62(1):66-71
74. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43(8):1609-11
75. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev 2002(2):CD003673
76. de Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 2008;3(1):e1475
77. Corbett A, Ballard C. New and emerging treatments for Alzheimer's disease. Expert Opin Emerg Drugs 2012;17(2):147-56
78. Shi JQ, Shen W, Chen J, et al. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 2011;1368:239-47
79. Corbett A, Ballard C. The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs. Evid Based Med 2014; Epub ahead of print
80. Remington R, Chan A, Paskavitz J, et al. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to laterstage Alzheimer's disease: a placebocontrolled pilot study. Am J Alzheimers Dis Other Demen 2009;24(1):27-33
81. Tong XK, Nicolakakis N, Fernandes P, et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis 2009;35(3):406-14
82. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74(12):956-64
83. Geldenhuys WJ, Van der Schyf CJ. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev Neurother 2009;9(7):1073-85
84. Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010;13(8):1021-33
85. Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry 2011;26(5):536-44
86. Preskorn SH, Gawryl M, Dgetluck N, et al. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract 2014;20(1):12-24
87. Prickaerts J, van Goethem NP, Chesworth R, et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2012;62(2):1099-110
88. Foster DJ, Choi DL, Conn PJ, et al. Activation of M and M muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Neuropsychiatr Dis Treat 2014;10:183-91
89. Ballard C, Kahn Z, Corbett A. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drugs Aging 2011;28(10):769-77
90. van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. CNS Neurosci Ther 2011;17(5):428-41
91. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72(1):41-52
92. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebocontrolled, multicentre trial. Lancet Neurol 2009;8(7):613-18
93. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(10):969-77
94. Marsh L, Biglan K, Gerstenhaber M, et al. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009;24(2):277-82
95. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75(5):448-55
96. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-78
97. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
98. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011;26(10):1851-8
99. Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007;68(20):1726-9
100. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16